• Article highlight
  • Article tables
  • Article images

Article Metrics




Downlaod Files

   


Article Access statistics

Viewed: 727

PDF Downloaded: 521


Get Permission Manasa R, Prakruthi M, Naik R, and Shivananjappa: Interrelationship between Gut microbiota and Parkinson’s disease


Introduction

Gut microbiota (GM) contains 100 trillion bacteria and some viruses, fungi, archaea. These microbes are 10 times greater than the number of cells present in the human body. GM contains 3 million genes which is 150 times more than the human genome. 1/3rd of the GM is similar in most people, while 2/3rd is specific for each individual. A study revealed that microbial fingerprint is unique for an individual and distinguishes him from others. 1 50-60% of the GM cannot be cultured as they have host-to-host transmission. 2, 3 Parkinson’s disease (PD) is the most common second neurodegenerative disorder which affects 1-2 people per 1000 population in the world. 4 PD affects about 7-10 million people in the world, 5 this number may double by 2030 due to aging of the people. 6 A study says that Asians are less affected than the western people and their genetic causes of PD are distinct. 7 China is the leading country with a greater number of PD patients. In 2005, it is 48% which may reach 57% by 2030 [Figure 1].

Figure 1

Distribution of individuals with Parkinson’s disease by country from 2005-2030. 8

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/466e899c-8094-4b2a-9b0d-fccb75134ec1image1.png

Parkinson’s disease

Parkinson's disease (PD) is a neurodegenerative disorder which causes muscular rigidity, akinesia, tremor, difficulty in walking and slowness of movement. Other symptoms include depression, dementia and dysfunction of ANS, CNS and ENS. There is a dopaminergic loss in substantia nigra pars compacta (SNpc) and it also causes α-synucleinopathy. 9, 10 80% of PD patients suffer from constipation. 11 The incidences of PD are probably higher in people between the ages 60-64 and lower at the age of 35-39 [Figure 2]

Gut microbiota and Parkinson’s disease:

GM contains one trillion microbes, among which bacteria is the dominant species in the GI tract. Bacteria contain mainly 4 phyla: Bacteroidetes, Firmicutes, Actinobacteria and Proteobacteria. 12 Helicobacter pylori is the extensively studied microbe in association with PD. H. pylori inhibits the absorption of Levodopa (drug to manage PD) and causes motor impairments. 13 PD is also associated with SIBO (Small Intestinal Bacterial Growth), excessive bacterial growth in the small intestine and it causes motor impairments. 14, 15 PD patients fecal sample analysis shows higher level of Enterobacteriaceae, which causes postural instability, 16 and lower levels of Prevotellaceae family of Bacteria, they are commensals which produce mucin and neuroactive SCFAs (propionate, acetate and butyrate). Decreased Prevotellaceae level in turn reduces the mucin synthesis, increases intestinal permeability and in the development of α-synucleinopathy. Lower prevotellaceae is also associated with increase in Lactobacillaceae, which in turn reduces the level of ghrelin (gut hormone), which is involved in nigrostriatal dopamine activity. 17 Another study reports that fecal sample of PD patient’s showincreased levels of proteobacteria of the genus Ralstonia and reduced level of bacteria of genera Roseburia, Blautia and Copococcus. But no change in the Bifido bacteria level. 18

Figure 2

Parkinson’s disease incidence and age 19.

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/466e899c-8094-4b2a-9b0d-fccb75134ec1image2.jpeg

Etiology of Parkinson’s disease:

The etiology of PD still remains unclear. It is mainly characterized by α-synucleinopathy (deposition of insoluble polymers of α-synuclein in the neuronal body and forms Lewy bodies). These Lewy bodies cause neurodegeneration and neuronal death. 20, 21 PD is associated with depauperation of dopaminergic neurons in the substantia nigra pars compacta (SNc), which causes dopamine deficiency. 22, 23, 24 Decrease in the dopamine in the basal ganglia causes motor symptoms like bradykinesia, rigidity and tremor [.Figure 3]. The non-motor symptoms include gastrointestinal dysfunction, sleep disturbances, neuropsychiatric disorders (depression, apathy, cognitive impairment, and psychosis), sensory alterations (pain, olfactory impairment). 25 Dopamine modulators are administered to manage PD, even though it has serious side effects, limited benefit and may not be effective in the later stages of PD. 24, 25, 26 PD causes constipation which is associated with neurodegeneration of ENS, 27 α-synuclein accumulation with increased oxidative stress, local inflammation and intestinal permeability. 28, 29

Figure 3

Etiology of Parkinson’s disease.30

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/466e899c-8094-4b2a-9b0d-fccb75134ec1image3.png

Gastrointestinal dysfunction in Parkinson’s disease:

According to Edwards et al31 PD patients have GI dysfunctions like abnormal salivation, constipation, dysphagia, nausea and defecatory dysfunction. Hypersalivation in PD patients is due to decreased swallowing frequency and it is symptomatic in 50% of PD patients. 32 Oropharyngeal dysfunction occurs in the oesophageal body or in the oesophageal sphincter among 60-70% of PD patients.28, 29, 30 Aspiration pneumonia occurs due to dysphagia in 15-55% of PD patients. 32, 33, 34 Impaired gastric emptying is the important characteristic of PD patients with symptoms like early satiety, bloating, abdominal discomfort and nausea. 35 Amplitude of stomach contractions has also been reduced in PD patients. 36 Delayed gastric emptying causes impaired absorption of L-dopa and increases motor fluctuations. 37 Small bowel dysmotility may be due to SIBO (small Intestinal Bacterial Overgrowth), which is increased in PD patients. 38 Constipation may be an early manifestation for PD patients. 39, 40, 41, 42, 43, 44 Colon transit time may be increased even in PD patients with asymptomatic constipation. 45 and its severity causes megacolon. 46 Incomplete evacuation and excessive straining are the symptoms of defecatory dysfunction. 47, 48

Figure 4

Difference in the GI system in normal and Parkinson’s disease. 49

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/466e899c-8094-4b2a-9b0d-fccb75134ec1image4.png

Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson’s Disease

Toll-like-receptors (TLR) ligands are produced by the gut microbiota; under certain conditions it can exert pro-inflammatory effects. 50 Under physiological conditions, gut has a high tolerance to TLR ligands, where as in altered gut microbiota activate TLRs which trigger downstream signalling pathways creates inflammation and oxidative stress in gut and brain in the PD patients. TLR2 and TLR4 are two major TLRs evidenced in PD patients. 50 They can trigger neurotoxicity upon their activation; in contrast they can clear misfolded α-synuclein, being neuroprotective. 51

Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson’s disease

Altered GM, induces abnormal production of inflammatory cytokines, which causes neuroinflammation in PD patients. 52 Inflammatory cytokines like IL-1β, IL-8 and TNF-α in the serum causes neurotoxicity, disruption of blood brain barrier and increases microglia-mediated inflammation. 53, 54 IL-6 is the major cytokine elevated in PD patients compared to controls. SIL-2-R and TNF- α are also associated with severe symptoms of PD. It may be noted that non-motor symptoms like fatigue and depression are generated via inflammatory mechanisms. 55

Structural changes of gut microbiota in Parkinson’s disease

To analyse the structural changes, putative cellulose degrading bacteria like Ruminococcus, Blautia and Faecalibacterium and putative pathobionts like Proteus, Enterococcus, Escherichia-Shigella, Streptococcus were measured in healthy controls and PD patients. 56 The putative cellulose degraders were decreased, whereas putative pathobionts were increased, which in turn decreases the production of SCFAs (Short Chain Fatty Acids) and increase the production of neurotoxins and endotoxins. These changes in the gut microbiota are associated with PD pathology. 56

Short chain fatty acids (SCFAs and gut microbiota in Parkinson's disease

SCFAs like butyrate, propionate and acetate are significantly lower in PD patients than the healthy controls of same age. 57 whereas valerate, isovalerate and iso-butyrate concentration remains same with control and the PD patients. These SCFAs can cross the brain and regulate the microglial activation. 58 SCFAs can cause motor dysfunctions in PD patients. 59

Conclusion

GM is a potential modulator of brain and behaviour. It can directly or indirectly modify our brain neurochemistry. There is a variation in the GM in PD patients, which can be used as a biomarker to analyse PD pathogenesis. There is still a need to achieve the proper inter-relationship between GM and PD. There is no proper treatment to cure the PD patients, even though Levodopa is an anti-parkinsonian medicine, it has its own limitations. Further study is required to manage the gut microbiota and Parkinson’s disease.

Source of Funding

None.

Conflict of Interest

None.

References

1 

Eric A. Franzosa Katherine Huang James F. Meadow Dirk Gevers Katherine P. Lemon Brendan J. M. Bohannan Identifying personal microbiomes using metagenomic codesProce National Academy Sci201511222E29308

2 

Alan W. Walker Sylvia H. Duncan Petra Louis Harry J. Flint Phylogeny, culturing, and metagenomics of the human gut microbiotaTrends Microbiol201422526774

3 

H P Browne S C Forster B O Anonye N Kumar B A Neville M D Stares Culturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulationNat201653376045436

4 

Ole-Bjørn Tysnes Anette Storstein Epidemiology of Parkinson’s diseaseJ Neural Transmission201712489015

5 

A T Nair V Ramachandran N M Joghee S Antony G Ramalingam Gut Microbiota Dysfunction as Reliable Non-invasive Early Diagnostic Biomarkers in the Pathophysiology of Parkinson's Disease: A Critical ReviewJ Neurogastroenterol Motil20182413042

6 

E. R. Dorsey R. Constantinescu J. P. Thompson K. M. Biglan R. G. Holloway K. Kieburtz Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030Neurol20076853846

7 

W Muangpaisan H Hori C Brayne Systematic Review of the Prevalence and Incidence of Parkinson’s Disease in AsiaJ Epidemiol200919628193

8 

http://image.slidesharecdn.com/dorseymatrc2013dorseyray-140101111752-phpapp02/95/using-technology-to-transform-care-for-patients-with-parkinson-disease-5-638.

9 

E C Wolters H Braak Parkinson’s disease: premotor clinico-pathological correlationsParkinson’s Disease and Related Disorders2006SpringerVienna30919

10 

D Sulzer Multiple hit hypotheses for dopamine neuron loss in Parkinson's diseaseTrends Neurosci200730524450

11 

A Ueki M Otsuka Life style risks of Parkinson?s disease: Association between decreased water intake and constipationJ Neurol2004251S7vii1823

12 

J M Rodríguez K Murphy C Stanton R P Ross O I Kober N Juge The composition of the gut microbiota throughout life, with an emphasis on early lifeMicrobial Ecol Health Dis20152626050

13 

G Çamcı S Oğuz Association between Parkinson's Disease and Helicobacter PyloriJ Clin Neurol201612214750

14 

A Fasano F Bove M Gabrielli M Petracca M A Zocco E Ragazzoni The role of small intestinal bacterial overgrowth in Parkinson's diseaseMov Disord201328912419

15 

Ai Huey Tan Sanjiv Mahadeva Abdul Malik Thalha Peter R. Gibson Chiun Khang Kiew Chia Ming Yeat Small intestinal bacterial overgrowth in Parkinson's diseaseParkinsonism Relt Disord201420553540

16 

F Scheperjans V Aho P A. B. Pereira K Koskinen L Paulin E Pekkonen Gut microbiota are related to Parkinson's disease and clinical phenotypeMov Dis20153033508

17 

Z. B. Andrews D. Erion R. Beiler Z.-W. Liu A. Abizaid J. Zigman Ghrelin Promotes and Protects Nigrostriatal Dopamine Function via a UCP2-Dependent Mitochondrial MechanismJ Neurosci200929451405765

18 

A Keshavarzian S J Green P A Engen R M Voigt A Naqib C B Forsyth Colonic bacterial composition in Parkinson's diseaseMov Disord20153010135160

19 

D Twelves K S M Perkins C Counsell Systematic review of incidence studies of Parkinson's diseaseMov Dis: Official J Mov Disord Soc2003181931

20 

E C Wolters H Braak Parkinson’s disease: premotor clinico-pathological correlationsParkinson’s Dis Relt Disord200630919Springer

21 

D Sulzer Multiple hit hypotheses for dopamine neuron loss in Parkinson's diseaseTrends Neurosci200730524450

22 

T G Beach H A Shill C H Adler L I Sue L Vedders L F Lue Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disordersActa Neuropathol20101196689702

23 

Heiko Braak Magdalena Sastre Jürgen R. E. Bohl Rob A. I. de Vos Kelly Del Tredici Parkinson’s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neuronsActa Neuropathol2007113442129

24 

Lorraine V Kalia Anthony E Lang Parkinson's diseaseLancet2015386896912

25 

Alfonso Fasano Naomi P Visanji Louis W C Liu Antony E Lang Ronald F Pfeiffer Gastrointestinal dysfunction in Parkinson's diseaseLancet Neurol201514662539

26 

A. H. V. Schapira M. Emre P. Jenner W. Poewe Levodopa in the treatment of Parkinson’s diseaseClin Interv Aging2009169229

27 

M G Cersosimo E E Benarroch Pathological correlates of gastrointestinal dysfunction in Parkinson's diseaseNeurobiol Dis201246355964

28 

Christopher B. Forsyth Kathleen M. Shannon Jeffrey H. Kordower Robin M. Voigt Maliha Shaikh Jean A. Jaglin Increased Intestinal Permeability Correlates with Sigmoid Mucosa alpha-Synuclein Staining and Endotoxin Exposure Markers in Early Parkinson's DiseasePLoS ONE2011612e28032

29 

D Devos T Lebouvier B Lardeux M Biraud T Rouaud H Pouclet Colonic inflammation in Parkinson's diseaseNeurobiol Dis201350428

30 

https://www.drprempillay.org/wp-content/uploads/2015/08/ParkinsonsDisease.png

31 

L. L. Edwards E. M. M. Quigley R. F. Pfeiffer Gastrointestinal dysfunction in Parkinson's disease: Frequency and pathophysiologyNeurol1992424726

32 

M. Bushmann S. M. Dobmeyer L. Leeker J. S. Perlmutter Swallowing abnormalities and their response to treatment in Parkinson's diseaseNeurol198939101309

33 

J. A. Castell B. T. Johnston A. Colcher Q. Li R. M. Gideon D. O. Castell Manometric abnormalities of the oesophagus in patients with Parkinson’s diseaseNeurogastroenterol Motil20011343614

34 

F S Monte F P da Silva-Júnior P Braga-Neto M Â Nobre e Souza V M Sales de Bruin Swallowing abnormalities and dyskinesia in Parkinson's diseaseMov Disord200520445762

35 

I Soykan Z Lin J P Bennett R W Mccallum Gastric myoelectrical activity in patients with Parkinson's disease (Evidence of a Primary Gastric Abnormality)Dig Dis Sci19994492731

36 

M M Unger K Hattemer J C Möller K Schmittinger K Mankel K Eggert Real-time visualization of altered gastric motility by magnetic resonance imaging in patients with Parkinson's diseaseMov Disord20102556238

37 

R. Djaldetti J. Baron I. Ziv E. Melamed Gastric emptying in Parkinson's disease: Patients with and without response fluctuationsNeurol199646410514

38 

A Fasano F Bove M Gabrielli M Petracca M A Zocco E Ragazzoni The role of small intestinal bacterial overgrowth in Parkinson's diseaseMov Dis201328912419

39 

Maria G. Cersosimo Eduardo E. Benarroch Autonomic involvement in Parkinson's disease: Pathology, pathophysiology, clinical features and possible peripheral biomarkersJ Neurol Sci20123131-25763

40 

Ronald F. Pfeiffer Gastrointestinal dysfunction in Parkinson’s diseaseParkinsonism Relt Disord2011171105

41 

Ronald F Pfeiffer Gastrointestinal dysfunction in Parkinson's diseaseLancet Neurol20032210716

42 

M.F Siddiqui S Rast M.J Lynn A.P Auchus R.F Pfeiffer Autonomic dysfunction in Parkinson's disease: a comprehensive symptom surveyParkinsonism Relt Disord20028427784

43 

Jost W. H. Eckardt V. F. Constipation in Idiopathic Parkinson's DiseaseScand J Gastroenterol20033876816

44 

R Sakakibara M Kishi E Ogawa F Tateno T Uchiyama T Yamamoto Bladder, Bowel, and Sexual Dysfunction in Parkinson's DiseaseParkinson's Dis20112011121

45 

R Sakakibara T Odaka T Uchiyama M Asahina K Yamaguchi T Yamaguchi Colonic transit time and rectoanal videomanometry in Parkinson's diseaseJ Neurol, Neurosurg Psychiatry200374226872

46 

W. J. Kupsky M. M. Grimes J. Sweeting R Bertsch L. J. Cote Parkinson's disease and megacolon: Concentric hyaline inclusions (Lewy bodies) in enteric ganglion cellsNeurol19873771253

47 

J S Kim H Y Sung K S Lee Y I Kim H T Kim Anorectal dysfunctions in Parkinson's diseaseJ Neurol Sci20113101-214451

48 

H Y Sung M G Choi Y I Kim K S Lee J S Kim Anorectal manometric dysfunctions in newly diagnosed, early-stage Parkinson's diseaseJ Clin Neurol2012831849

49 

https://www.gutmicrobiotaforhealth.com/wp-content/uploads/2016/12/parkinson.jpg

50 

V Caputi M Giron Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson’s DiseaseInt J Mol Sci20181961689

51 

C D Rietdijk R J Van Wezel J Garssen A D Kraneveld Neuronal toll-like receptors and neuro-immunity in Parkinson's disease, Alzheimer's disease and stroke2016196

52 

A Paun C Yau J S Danska Immune recognition and response to the intestinal microbiome in type 1 diabetesJ Autoimm201671108

53 

Lourdes Álvarez-Arellano Helicobacter pyloriand neurological diseases: Married by the laws of inflammationWorld J Gastrointest Pathophysiol201454400

54 

Michelle L. Block Luigi Zecca Jau-Shyong Hong Microglia-mediated neurotoxicity: uncovering the molecular mechanismsNat Rev Neurosci2007815769

55 

D Lindqvist E Kaufman L Brundin S Hall Y Surova O Hansson Non-Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Inflammatory Cytokines in SerumPLoS ONE2012710e47387

56 

W Li X Wu X Hu T Wang S Liang Y Duan Structural changes of gut microbiota in Parkinson’s disease and its correlation with clinical featuresSci China Life Sci20176011122333

57 

M M Unger J Spiegel D Klaus-Ulrich D Grundmann H Philippeit J Bürmann Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controlsParkinsonism Relt Disord2016326672

58 

J Huuskonen T Suuronen T Nuutinen S Kyrylenko A Salminen Regulation of microglial inflammatory response by sodium butyrate and short-chain fatty acidsBr J Pharm2004141587480

59 

Timothy R. Sampson Justine W. Debelius Taren Thron Stefan Janssen Gauri G. Shastri Zehra Esra Ilhan Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s DiseaseCell20161676146980



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.